Todd C Davis bought $986K of Pelthos Therapeutics (PTHS)
Executed Jun 11, disclosed Jun 15, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 15), the stock returned -2.9% (delay-adjusted); from the execution session (Jun 11), -5.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Todd C Davis (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). Across 1 priced purchase filing, the average 21-session return was -5.4% from execution and -2.9% from disclosure (delay-adjusted; derived). The largest single filing was $986K of PTHS (35,445 sh × $27.80, as filed), executed Jun 11.
Healthcare · Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→